Anna McCarter
YOU?
Author Swipe
View article: ETS1 Recruits the Canonical Baf Complex to Reactivate the Hematopoietic Stem Cell <i>MYB</i> Enhancer in the T-Cell Leukemia Context
ETS1 Recruits the Canonical Baf Complex to Reactivate the Hematopoietic Stem Cell <i>MYB</i> Enhancer in the T-Cell Leukemia Context Open
In T-cell acute lymphoblastic leukemia (T-ALL), Notch variants are the most common oncogenic mutations, but clinical trials showed excessive toxicity of pan-Notch inhibitors. In response, we refocused to ETS1, which we and others previousl…
View article: Trametinib Inhibits Lymphatic Vessel Invasion of Bone in a Mouse Model of Gorham-Stout Disease
Trametinib Inhibits Lymphatic Vessel Invasion of Bone in a Mouse Model of Gorham-Stout Disease Open
Objective: Gorham-Stout disease (GSD) is a rare lymphatic anomaly that can be caused by somatic activating mutations in KRAS . This discovery has led investigators to suggest that MEK inhibitors could be a novel treatment for GSD. However,…
View article: KRAS-driven model of Gorham-Stout disease effectively treated with trametinib
KRAS-driven model of Gorham-Stout disease effectively treated with trametinib Open
Gorham-Stout disease (GSD) is a sporadically occurring lymphatic disorder. Patients with GSD develop ectopic lymphatics in bone, gradually lose bone, and can have life-threatening complications, such as chylothorax. The etiology of GSD is …
View article: Lymphatics in bone arise from preexisting lymphatics
Lymphatics in bone arise from preexisting lymphatics Open
Bones do not normally have lymphatics. However, patients with generalized lymphatic anomaly (GLA) or Gorham-Stout disease (GSD) develop ectopic lymphatics in bone. Despite growing interest in the development of tissue-specific lymphatics, …
View article: ETS1 Promotes Context-Dependent Activation of Notch Signals in T-Cell Leukemia
ETS1 Promotes Context-Dependent Activation of Notch Signals in T-Cell Leukemia Open
Notch is a signaling pathway involved in cellular growth and development. Aberrant activation of the Notch pathway is prevalent in cancer, including more than 60% of cases of T-cell acute lymphoblastic leukemia (T-ALL). Clinical trials usi…